Teva is developing laquinimod tablets as a new oral treatment for MS. Laquinimod has immunomodulating properties. In a previous clinical study laquinimod showed evidence of biological activity by reducing the number of acute brain lesions. The duration of the current study is 36 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
306
Reduction of brain lesions in the last 4 months of the study
Time frame: 36 weeks
Relapse rate
Time frame: 36 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.